J
Jeffrey J. Rade
Researcher at University of Massachusetts Medical School
Publications - 70
Citations - 6497
Jeffrey J. Rade is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Thromboxane & Platelet. The author has an hindex of 24, co-authored 68 publications receiving 5733 citations. Previous affiliations of Jeffrey J. Rade include Johns Hopkins University School of Medicine & University of Massachusetts Amherst.
Papers
More filters
Journal ArticleDOI
Comparison of Prevalence, Presentation, and Prognosis of Acute Coronary Syndromes in ≤35 years, 36 - 54 years, and ≥ 55 years Patients.
TL;DR: Very young patients comprised ∼1% of all ACS cases but had much more prevalence of modifiable risk factors and significantly worse mortality.
Journal ArticleDOI
Adenovirus-mediated expression of tissue plasminogen activator does not alter endothelial cell proliferation and invasion
TL;DR: The purpose of this study was to characterize the effect of adenovirus-mediated tPA transgene expression on cultured EC angiogenic activity and determine its dependence on plasmin-mediated proteolysis.
Journal ArticleDOI
Deficiency of MMP1a (Matrix Metalloprotease 1a) Collagenase Suppresses Development of Atherosclerosis in Mice: Translational Implications for Human Coronary Artery Disease.
Elizabeth K. Fletcher,Yanling Wang,Laura K. Flynn,Susan E. Turner,Jeffrey J. Rade,Carey Kimmelstiel,Paul A. Gurbel,Kevin P. Bliden,Lidija Covic,Athan Kuliopulos +9 more
TL;DR: In this paper, MMP1a deficiency led to significant reductions in plaque monocytes/macrophages, SMCs, and necrosis, with increases in collagen content, and showed evidence for an important role for the MMP 1a collagenase in atherosclerotic lesion development and leukocyte behavior.
Journal ArticleDOI
Differential Impact of Serial Measurement of Nonplatelet Thromboxane Generation on Long-Term Outcome After Cardiac Surgery.
Nikolaos Kakouros,Tyler J Gluckman,John V. Conte,Thomas S. Kickler,Katherine Laws,Bruce A. Barton,Jeffrey J. Rade +6 more
TL;DR: Long‐term nonplatelet thromboxane generation after coronary artery bypass graft surgery is a novel risk factor for 5‐year adverse outcome, including death, and appears to be driven predominantly by inflammation.
Journal ArticleDOI
FFR-guided PCI - FAME may not be so fleeting after all
TL;DR: Recommendations are derived from studies, most notably the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, which showed that angiography-guided PCI plus medical therapy was no better at preventing death or myocardial infarction than medical therapy alone.